Stock listing
NASDAQ:CTOR Citius Oncology, Inc. Stock
Home listing (NASDAQ) of Citius Oncology, Inc.
Follow Citius Oncology, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CTOR
$0.504 USD -0.054 (-9.7%)
Close on Nov 20, 2026
- Day range
- $0.502 – $0.570 USDNov 20, 2026
- Volume
- 52,634 sharesNov 20, 2026
- Market cap
- $53.25M USDAt the close on Nov 20, 2026 · price × 105.8M shares outstanding
- 52-week range
- $0.491 – $1.830 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $83,583 USDMedian day 83,079 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CTOR · Home | $0.504 USD | -0.054 (-9.7%) | 52,634 | $0.570 | $0.570 | $0.502 | $0.557 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CTOR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.504 | -0.054 | -9.7% | $0.570 | $0.570 | $0.502 | 52,634 | |
| $0.557 | +0.010 | +1.8% | $0.545 | $0.572 | $0.540 | 152,055 | |
| $0.548 | +0.013 | +2.4% | $0.552 | $0.595 | $0.548 | 177,306 | |
| $0.535 | -0.039 | -6.8% | $0.559 | $0.576 | $0.525 | 83,079 | |
| $0.574 | +0.051 | +9.9% | $0.522 | $0.591 | $0.522 | 224,751 | |
| $0.522 | -0.033 | -5.9% | $0.540 | $0.567 | $0.520 | 73,333 | |
| $0.555 | -0.008 | -1.4% | $0.554 | $0.573 | $0.545 | 44,832 | |
| $0.563 | +0.013 | +2.4% | $0.562 | $0.563 | $0.538 | 84,896 | |
| $0.550 | +0.040 | +7.9% | $0.520 | $0.585 | $0.520 | 106,688 | |
| $0.510 | +0.009 | +1.9% | $0.541 | $0.541 | $0.502 | 195,332 | |
| $0.500 | -0.047 | -8.6% | $0.548 | $0.577 | $0.494 | 145,279 | |
| $0.547 | -0.003 | -0.5% | $0.556 | $0.595 | $0.540 | 79,857 | |
| $0.550 | -0.044 | -7.4% | $0.608 | $0.622 | $0.547 | 188,031 | |
| $0.594 | +0.040 | +7.2% | $0.589 | $0.694 | $0.554 | 378,696 | |
| $0.554 | +0.025 | +4.6% | $0.527 | $0.563 | $0.500 | 283,279 | |
| $0.530 | -0.047 | -8.2% | $0.580 | $0.607 | $0.506 | 193,082 | |
| $0.577 | -0.034 | -5.6% | $0.629 | $0.629 | $0.571 | 91,806 | |
| $0.611 | +0.015 | +2.6% | $0.634 | $0.646 | $0.571 | 134,810 | |
| $0.596 | +0.016 | +2.8% | $0.612 | $0.689 | $0.539 | 874,207 | |
| $0.580 | -0.120 | -17.2% | $0.720 | $0.720 | $0.510 | 70,533 | |
| $0.700 | -0.001 | -0.1% | $0.729 | $0.730 | $0.655 | 38,020 | |
| $0.700 | +0.029 | +4.4% | $0.705 | $0.760 | $0.652 | 22,886 | |
| $0.671 | -0.039 | -5.5% | $0.730 | $0.747 | $0.660 | 97,444 | |
| $0.710 | -0.058 | -7.5% | $0.756 | $0.760 | $0.700 | 40,000 | |
| $0.768 | +0.022 | +2.9% | $0.770 | $0.770 | $0.750 | 11,700 | |
| $0.746 | -0.038 | -4.8% | $0.760 | $0.770 | $0.745 | 11,000 | |
| $0.784 | -0.008 | -1.0% | $0.811 | $0.811 | $0.750 | 27,600 | |
| $0.792 | -0.021 | -2.6% | $0.800 | $0.844 | $0.743 | 96,700 | |
| $0.813 | -0.027 | -3.2% | $0.860 | $0.860 | $0.780 | 67,900 | |
| $0.840 | +0.005 | +0.6% | $0.842 | $0.880 | $0.800 | 71,000 | |
| $0.835 | -0.016 | -1.9% | $0.870 | $0.870 | $0.820 | 56,400 | |
| $0.851 | +0.001 | +0.1% | $0.847 | $0.901 | $0.847 | 105,500 | |
| $0.850 | -0.024 | -2.7% | $0.858 | $0.920 | $0.812 | 109,800 | |
| $0.874 | -0.076 | -8.0% | $0.930 | $0.930 | $0.860 | 85,500 | |
| $0.950 | -0.030 | -3.1% | $0.999 | $1.050 | $0.914 | 208,400 | |
| $0.980 | -0.030 | -3.0% | $1.070 | $1.070 | $0.942 | 99,600 | |
| $1.010 | -0.040 | -3.8% | $1.090 | $1.090 | $1.000 | 96,700 | |
| $1.050 | +0.020 | +1.9% | $1.025 | $1.130 | $1.000 | 186,000 | |
| $1.030 | -0.020 | -1.9% | $1.040 | $1.080 | $1.020 | 43,600 | |
| $1.050 | 0.000 | 0.0% | $1.070 | $1.070 | $1.020 | 26,700 | |
| $1.050 | +0.040 | +4.0% | $1.030 | $1.080 | $1.007 | 40,700 | |
| $1.010 | -0.060 | -5.6% | $1.050 | $1.070 | $0.985 | 55,800 | |
| $1.070 | +0.025 | +2.4% | $1.000 | $1.120 | $1.000 | 117,000 | |
| $1.045 | -0.095 | -8.3% | $1.150 | $1.150 | $1.030 | 152,200 | |
| $1.140 | +0.120 | +11.8% | $1.050 | $1.155 | $1.010 | 336,900 | |
| $1.020 | +0.066 | +6.9% | $0.970 | $1.050 | $0.920 | 189,200 | |
| $0.954 | +0.098 | +11.4% | $0.890 | $0.984 | $0.853 | 184,400 | |
| $0.856 | -0.084 | -8.9% | $0.950 | $0.978 | $0.850 | 118,000 | |
| $0.940 | +0.022 | +2.4% | $0.920 | $0.988 | $0.915 | 69,200 | |
| $0.918 | +0.008 | +0.9% | $0.890 | $0.950 | $0.890 | 138,300 | |
| $0.910 | -0.030 | -3.2% | $0.920 | $0.940 | $0.868 | 47,900 | |
| $0.940 | +0.011 | +1.2% | $0.910 | $0.960 | $0.858 | 56,400 | |
| $0.929 | +0.069 | +8.0% | $0.913 | $0.940 | $0.872 | 220,800 | |
| $0.860 | +0.068 | +8.6% | $0.767 | $0.882 | $0.750 | 54,700 | |
| $0.792 | +0.014 | +1.8% | $0.800 | $0.800 | $0.778 | 13,900 | |
| $0.778 | +0.028 | +3.7% | $0.735 | $0.800 | $0.725 | 12,100 | |
| $0.750 | -0.013 | -1.7% | $0.770 | $0.777 | $0.725 | 16,600 | |
| $0.763 | -0.013 | -1.7% | $0.820 | $0.820 | $0.753 | 38,700 | |
| $0.776 | -0.014 | -1.8% | $0.800 | $0.800 | $0.754 | 21,700 | |
| $0.790 | +0.003 | +0.4% | $0.828 | $0.830 | $0.790 | 8,600 | |
| $0.787 | -0.023 | -2.8% | $0.791 | $0.820 | $0.752 | 17,000 | |
| $0.810 | +0.060 | +8.0% | $0.705 | $0.818 | $0.705 | 134,100 | |
| $0.750 | +0.006 | +0.8% | $0.759 | $0.760 | $0.722 | 16,600 | |
| $0.744 | -0.015 | -2.0% | $0.721 | $0.755 | $0.721 | 13,400 | |
| $0.759 | +0.006 | +0.8% | $0.752 | $0.773 | $0.710 | 52,100 |
- Ticker
- NASDAQ:CTOR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Latest deck · Dec 1, 2025
Investor Presentation (December 2025)
Investor deck · 19 slides
Latest news
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Nov 11, 2026
Closed $0.555 (-1.4%) on Nov 11, 2026
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
Nov 4, 2026
Closed $0.547 (-0.5%) on Nov 4, 2026
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Oct 26, 2026
Closed $0.596 (+2.8%) on Oct 26, 2026
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Oct 12, 2026
Closed $0.813 (-3.2%) on Oct 12, 2026
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Aug 14, 2026
Closed $0.74 (-18.7%) on Aug 17, 2026
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
Aug 12, 2026
Closed $0.812 (+11.2%) on Aug 12, 2026
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
Aug 5, 2026
Closed $0.785 (+18.9%) on Aug 5, 2026
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Jul 21, 2026
Closed $0.57 (0.0%) on Jul 21, 2026
Citius Oncology, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 27 in the last 12 months · 59 in all · newest Nov 11, 2026 · oldest 2023
- Decks
- 4 decks · latest Dec 1, 2025
Where Citius Oncology, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CTOR · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CTOR | BOATS | United States | USD |
Valuation
Price/book 1.3× against a median of 1.1×: 7th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $36.69M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.66
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Citius Oncology, Inc. · NASDAQ:CTOR | US$53.25M | US$36.69M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.66 |
| Korea Pharma Co., Ltd. · KRX:032300 | US$59.92M | US$47.49M | n/a | 0.7× | 13.4× | 1.1× | −0.8% | 0.2× | n/a |
| High Tech Pharm. Co., Ltd. · KRX:106190 | US$59.61M | US$57.37M | 6.7× | 1.1× | 4.3× | 0.6× | 17.2% | 0.0× | n/a |
| Valiant Laboratories Ltd. · NSE:VALIANTLAB | US$55.63M | US$55.72M | 31.8× | 1.4× | 13.5× | 1.6× | 4.3% | 0.1× | n/a |
| Samik Pharm Co., Ltd. · KRX:014950 | US$52.45M | US$28.27M | n/a | 0.6× | 12.0× | 1.0× | −2.4% | 0.0× | n/a |
| Chi Sheng Pharma & Biotech Co., Ltd. · TPEX:4111 | US$49.92M | US$35.59M | 8.7× | 0.8× | 4.3× | 1.2× | 13.3% | 0.0× | n/a |
| Biome Australia Ltd · ASX:BIO | US$49.01M | US$48.63M | 20.5× | 3.1× | 34.2× | 7.9× | 15.1% | 0.3× | n/a |
| Shivalik Rasayan Ltd · NSE:SHIVALIK | US$48.94M | US$48.94M | 33.2× | 1.2× | 6.4× | 0.8× | 3.6% | 0.0× | n/a |
| Verrica Pharmaceuticals Inc. · NASDAQ:VRCA | US$47.07M | US$45.98M | n/a | 2.0× | n/a | n/a | −189.2% | n/a | 2.03 |
| Albert David Ltd · NSE:ALBERTDAVD | US$46.97M | US$19.58M | 15.1× | 0.5× | 5.1× | 1.0× | 7.6% | 0.1× | n/a |
| LTR Pharma Limited · ASX:LTP | US$46.45M | US$33.44M | n/a | 275× | n/a | 3.5× | n/a | 0.0× | n/a |
| Median of the others | US$49.47M | US$46.74M | 17.8× | 1.2× | 9.2× | 1.1× | 4.3% | 0.0× | 2.03 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Sep 2026
- -0.50 · 1 analyst
- Revenue, year to Sep 2026
- 10.39M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Myron Holubiak | Secretary |
Board
| Director | Role |
|---|---|
| Leonard Mazur | Chairman |
| Carol Webb | Director |
| Dennis M. McGrath | Director |
| Eugene Holuka | Director |
| Joel Mayersohn | Director |
| Jonathan Peri | Director |
| Myron Holubiak | Secretary |
| Robert Smith | Director |
| Suren Dutia | Director |
Events
- Next results
- Dec 22, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Aug 14, 2026 · After close | −18.7% |
| Q2 2026 | May 15, 2026 · After close | −13.9% |
| Q1 2026 | Feb 13, 2026 | 0.0% |
| Q4 2025 | Dec 23, 2025 · After close | −9.8% |
| Q3 2025 | Aug 12, 2025 · After close | +5.9% |
| Q2 2025 | May 14, 2025 · After close | −0.6% |
| Q1 2025 | Feb 17, 2025 | −5.6% |
| Q4 2024 | Dec 30, 2024 | +10.6% |
| Q3 2024 | Aug 28, 2024 | −3.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2025) | Investor deck | 19 slides | Dec 1, 2025 |
| Investor Presentation (October 2025) | Investor deck | 19 slides | Oct 23, 2025 |
| Investor Presentation (February 2025) | Investor deck | 28 slides | February 2025 |
| SPAC Merger (October 2023) | SPAC merger | 33 slides | Oct 24, 2023 |
Financings
| Raise | Date |
|---|---|
| Senior secured term loan with warrants Announced: US$10M–US$25M · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: Avenue Venture Opportunities Fund II, L.P. (up to $25 million senior secured term loan credit facility) Use of proceeds: LYMPHIR commercialization (sales force, market access, medical affairs, supply chain), working capital and general corporate purposes | May 5, 2026 |
| Warrant exercise of exercise of outstanding warrants for common stock Announced: about US$11.5M · US$0.9 a share · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: LYMPHIR commercialization (sales force, market access, medical affairs, supply chain), working capital and general corporate purposes | May 5, 2026 |
| Registered direct offering of common stock with unregistered warrants Closed: US$1.09 a share · Warrants at US$1.09 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR, working capital and general corporate purposes | Dec 10, 2025 |
| Private placement of common stock (or pre-funded warrants) and warrants Closed: US$1.09 a share · Warrants at US$1.09 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR, working capital and general corporate purposes | Dec 10, 2025 |
| Registered direct offering of common stock with accompanying unregistered warrants Closed: US$9M raised · US$1.75 a share · ½ warrant at US$1.84 for 66 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) | Sep 10, 2025 |
| Public offering of common stock and warrants Closed: US$9M raised · US$1.32 a share · Warrants at US$1.32 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Commercialization of LYMPHIR, including license milestone and royalty payments, plus working capital and general corporate purposes | Jul 17, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as TenX Keane Acquisition, a blank check company (SPAC). Priced at US$10.00 a unit on Oct 13, 2022.
- Price
- US$10.00 a unit
- Units offered
- 6,000,000 units
- Offering size
- US$60 million
- Underwriters' option
- Up to 900,000 more units
- Listing
- TENKU on the Nasdaq Global Market
- Underwriter
- Maxim Group LLC
- Units delivered
- On or about Oct 18, 2022
Steps
| Step | When |
|---|---|
| Filed publicly | May 19, 2021 |
| Amended 8 times | Newest Sep 12, 2022 |
| Shares registered with an exchange | Oct 13, 2022 |
| Declared effective by the SEC | Oct 13, 2022 |
| Final prospectus, with the price | Oct 14, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 14, 2022 |
| EFFECT · Notice that a registration is effective | Oct 13, 2022 |
| CERT · Exchange's certificate of listing | Oct 13, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 13, 2022 |
| CORRESP · Letter to the SEC | Oct 11, 2022 |
| CORRESP · Letter to the SEC | Oct 11, 2022 |
| S-1/A · Registration statement, amended | Sep 12, 2022 |
| CORRESP · Letter to the SEC | Jul 29, 2022 |
| S-1/A · Registration statement, amended | Jul 29, 2022 |
| UPLOAD · Letter from the SEC | Jul 26, 2022 |
All 27 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | May 24, 2022 |
| CORRESP · Letter to the SEC | May 12, 2022 |
| CORRESP · Letter to the SEC | May 12, 2022 |
| S-1/A · Registration statement, amended | May 11, 2022 |
| CORRESP · Letter to the SEC | May 11, 2022 |
| CORRESP · Letter to the SEC | May 11, 2022 |
| S-1/A · Registration statement, amended | Apr 1, 2022 |
| CORRESP · Letter to the SEC | Mar 8, 2022 |
| S-1/A · Registration statement, amended | Mar 8, 2022 |
| UPLOAD · Letter from the SEC | Sep 14, 2021 |
| CORRESP · Letter to the SEC | Aug 20, 2021 |
| S-1/A · Registration statement, amended | Aug 20, 2021 |
| UPLOAD · Letter from the SEC | Jul 19, 2021 |
| S-1/A · Registration statement, amended | Jun 30, 2021 |
| CORRESP · Letter to the SEC | Jun 29, 2021 |
| UPLOAD · Letter from the SEC | Jun 16, 2021 |
| S-1 · Registration statement | May 19, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 14, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Research and development | 6.42M | 4.93M | 4.24M | ||
| Operating income | -23.5M | -20.6M | -1.01M | -138.1K | |
| Interest expense | 218.0K | ||||
| Income before tax | -23.7M | -20.6M | -12.1M | ||
| Income tax | 1.06M | 576.0K | 576.0K | ||
| Net income | -24.8M | -21.1M | 2.42M | -12.7M | 380.8K |
| Earnings per share, basic | -0.34 | -0.31 | 0.27 | -0.19 | 0.12 |
| Earnings per share, diluted | -0.34 | -0.31 | 0.27 | -0.19 | 0.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Cash and equivalents | 3.92M | 112 | 32.7K | 26.5K | 289.2K |
| Inventory | 22.3M | 8.27M | |||
| Current assets | 27.5M | 11.0M | 58.2K | 7.73M | 377.3K |
| Total assets | 100.9M | 84.4M | 72.6M | 47.7M | 68.2M |
| Accounts payable | 13.2M | 3.71M | 1.29M | ||
| Current liabilities | 49.5M | 32.7M | 2.05M | 21.0M | 31.8K |
| Total liabilities | 56.1M | 38.2M | 22.2M | ||
| Shareholders' equity | 44.9M | 46.1M | 22.7M | 25.5M | 345.5K |
| Shares outstanding | 83.5M | 71.6M | 2.34M | 67.5M | 2.42M |
Cash flow
| Line | FY2025 | FY2024 | FY2024 | FY2023 |
|---|---|---|---|---|
| Cash from operations | -5.49M | 126.4K | -601.3K | -48.0K |
| Cash from investing | -5.75M | -5.00M | -1.32M | -67.3M |
| Cash from financing | 15.2M | 4.87M | 1.66M | 67.7M |
| Change in cash | 3.92M | 112 | -256.4K | 289.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 8-K · Current report | Oct 26, 2026 | Results | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| 8-K · Current report | Sep 29, 2026 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | Aug 26, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 26, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Aug 14, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 12, 2026 | Management or board change | SEC |
| 424B3 · Prospectus | Aug 5, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 5, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 8, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 4, 2026 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 3, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jun 1, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| DEF 14C | May 29, 2026 | Meeting notice | SEC |
| S-3 · Registration statement | May 29, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 22, 2026 | Offer document | SEC |
| PRE 14C | May 19, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 6, 2026 | Offer document | SEC |
| 8-K · Current report | May 6, 2026 | Material contract | SEC |
| 424B3 · Prospectus | May 5, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 29, 2026 | Current report | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| 8-K · Current report | Mar 10, 2026 | Current report | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 3, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Feb 20, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Feb 13, 2026 | Quarterly report | SEC |
| DEF 14C | Jan 29, 2026 | Meeting notice | SEC |
| PRE 14C | Jan 20, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 9, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 9, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 5, 2026 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2025 | Results | SEC |
| 10-K · Annual report | Dec 23, 2025 | Annual report | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 22, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 9, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 1, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 1, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 27, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Sep 26, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 19, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 19, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 12, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 5, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 2, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 2, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 22, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Aug 20, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 424B3 · Prospectus | Aug 18, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 18, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jul 17, 2025 | Other filings | SEC |
| 424B4 · Prospectus | Jul 16, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 15, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 14, 2025 | Offer document | SEC |
| S-1 · Registration statement | Jul 14, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2025 | Current report | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | May 1, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Apr 28, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| 8-K · Current report | Apr 3, 2025 | Material contract | SEC |
| DEFA14C | Feb 24, 2025 | Other filings | SEC |
| DEF 14C | Feb 24, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Feb 14, 2025 | Quarterly report | SEC |
| PRE 14C | Feb 12, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 6, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Jan 27, 2025 | Annual report | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| 8-K · Current report | Jan 6, 2025 | Current report | SEC |
| 8-K · Current report | Dec 27, 2024 | Results | SEC |
| 10-K · Annual report | Dec 27, 2024 | Annual report | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 13, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 5, 2024 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Aug 30, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 30, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 30, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 30, 2024 | Insider trade | SEC |
| 8-K/A · Current report, amended | Aug 26, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Aug 16, 2024 | Acquisition or disposal | SEC |
| SC 13D · Big-stake notice | Aug 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 16, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 15, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 25-NSE | Aug 13, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2024 | Management or board change | SEC |
| 425 | Jul 19, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 19, 2024 | Material contract | SEC |
| SEC STAFF LETTER | Jul 16, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jul 15, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jul 12, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 11, 2024 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jul 11, 2024 | Offer document | SEC |
| S-4/A · Registration statement, amended | Jul 11, 2024 | Offer document | SEC |
| 425 | Jun 18, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 18, 2024 | Material contract | SEC |
| S-4/A · Registration statement, amended | Jun 17, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 17, 2024 | Other filings | SEC |
| 425 | Jun 6, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 6, 2024 | Current report | SEC |
| 8-K · Current report | May 21, 2024 | Material contract | SEC |
This page holds 200 of 280 filings. Open Filings
Cap table
Built by 6ix from Citius Oncology, Inc.’s releases · as of May 5, 2026
- Common shares
- 105,758,982
- Fully diluted
- 108,330,410
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 105,758,982 | |
| Warrants | 2,571,428 | Sep 10, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.09 · expire about Dec 2030 |
| Warrants · US$1.84 · expire about Mar 2031 |
| Warrants · US$1.32 · expire about Jul 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 105,758,982 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dennis M. McGrath Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Feb 7, 2023); Lucid Diagnostics Inc. (Chief Financial Officer · Since at least Oct 13, 2021); PAVmed Inc. (President and CFO · Since at least Feb 14, 2018); DarioHealth Corp. (Board Member · Since at least Oct 23, 2017) | Director · Since at least Aug 12, 2024 |
| Leonard Mazur Other companies: Citius Pharmaceuticals, Inc. (Co-Founder, CEO and Chairman of the Board of Directors · Since at least Mar 30, 2016); Canton Strategic Holdings, Inc. (Director · Jan 11, 2022 – Aug 9, 2024 · Past) | Chairman · Since at least Aug 12, 2024 |
| Myron Holubiak Other companies: Citius Pharmaceuticals, Inc. (Co-Founder, Executive Vice Chairman · Since at least Mar 28, 2018); Assembly Biosciences, Inc. (Director · May 30, 2018 – May 20, 2021 · Past) | Secretary · Since at least Aug 12, 2024 |
| Brian Hartzband Other companies: GMEX Robotics Corporation (President of U · Since at least Jul 1, 2026) | Director · Oct 13, 2022 – Oct 13, 2022 · Past |
| Carol Webb Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
| Cathy Jiang Other companies: Peace Acquisition Corp (CFO · Since at least May 21, 2026) | Director · Oct 13, 2022 – Oct 13, 2022 · Past |
| Eugene Holuka Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Oct 6, 2020) | Director · Since at least Aug 12, 2024 |
| Jaime Bartushak Other companies: Citius Pharmaceuticals, Inc. (Chief Financial Officer & Chief Business Officer · Since at least Oct 6, 2020) | Chief Financial Officer · Since at least Aug 12, 2024 |
| Joel Mayersohn Other companies: Peace Acquisition Corp (Director · Since at least May 21, 2026) | Director · Since at least Dec 12, 2024 |
| Myron S. Czuczman Other companies: Citius Pharmaceuticals, Inc. (Chief Medical Officer and EVP · Since at least Jul 14, 2020) | Chief Medical Officer · Since at least Aug 12, 2024 |
All 13 people
| Person | Seat |
|---|---|
| Robert Smith Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Mar 12, 2024) | Director · Since at least Aug 12, 2024 |
| Suren Dutia Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
| Jonathan Peri | Director · Since at least Aug 10, 2026 |
Log in to ask 6ix AI your own questions about Citius Oncology, Inc.